恶性肿瘤患者在接受化疗、放疗、靶向治疗及免疫治疗等抗肿瘤治疗时都可能引发恶心呕吐.化疗所致恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)是最为常见也是目前研究最为深入的不良反应;放疗所致恶心呕吐(radiation-induced nausea and vomiting,RINV)、靶向治疗及免疫治疗所致恶心呕吐(targeted therapy and immunotherapy-induced nausea and vomiting,TIINV)也越来越受到关注.本专家组在《化疗所致恶心呕吐全程管理上海专家共识(2018年版)》的基础上,根据近年来抗肿瘤治疗所致恶心呕吐(antineoplastic-induced nausea and vomiting,AINV)领域的循证医学新证据,结合上海一线肿瘤治疗专家的实际临床经验,最终形成《抗肿瘤治疗所致恶心呕吐全程管理上海专家共识(2024年版)》,以便进一步在上海地区积极、合理、规范、全程地预防和处理AINV,保障患者的治疗强度和医疗安全.
Abstract
Nausea and vomiting are common adverse reactions in tumor patients during anti-tumor therapy such as chemotherapy,radiotherapy,targeted therapy and immunotherapy.Although chemotherapy-induced nausea and vomiting(CINV)is the most common and the most intensively studied adverse event,radiation-induced nausea and vomiting(RINV),targeted therapy and immunotherapy-induced nausea and vomiting(TIINV)have also attracted more and more attention.Based on"Shanghai expert consensus on whole-process management of chemotherapy-induced nausea and vomiting(2018 edition)",as well as new medical evidence of antineoplastic-induced nausea and vomiting(AINV)and experience of Shanghai experts in this field,the expert group finally developed"Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting(2024 edition)".This consensus will guide doctors in Shanghai to standardize the whole-process management of AINV,and to ensure the treatment intensity and medical safety of patients.
维普
万方数据